Organ on Chip Market Analysis | 2022-2028

“The Organ on Chip Market was estimated at US$ 111 million in 2021 and is expected to grow at a CAGR of 28.43% during 2022-2028 to reach US$ 647.6 million in 2028”.

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Organs-on-chips (OOCs) are miniature plastic gadgets with biocompatible microfluidic chambers that house numerous living human cells in a 3D culture to mimic various physiological functions of body organs. A promising substitute for animal models is organs-on-chips that replicate the physiology of human organs at the cellular level.

Market Drivers

Utilizing pertinent innovative techniques from the fields of cell biology, microfabrication, microfluidics, material science, and nanotechnology, an OOC can be designed and developed. The precise chip design varies depending on the manufacturing process and the organ it mimics, but the fundamental structure typically doesn't change.

In the process of developing new drugs, OOCs are thought to be more relevant and accurate than cell cultures or animal models. These chips are expensive, though, and revamping processes for mass production are expensive as well. As a costly redesigning process could be a hardship for the relatively small enterprises engaged, high production costs are limiting the OOC market's expansion.

Additionally, the conceptual designing of bioreactor pumps for the perfusion of cell culture media, upkeep of the cell environment, mechanical stimuli, and the application of cell analysis techniques are all complicated and expensive. Pharmaceutical companies might not be able to purchase the chip because of the costs associated with manufacturing upscaling.

Making an OOC is also not an easy process; difficulties include replicating the architectural complexity of human tissues and organs on a device in a scaled-down manner, as well as linking and organizing them in the proper format for the interconnected systems to recreate the interactions between human tissues and organs.

A growing discipline called personalized medicine enables doctors to create customized treatments for their patients, i.e., to pick the finest medication at the ideal dosage based on each patient's requirements. It has a tremendous deal of potential to improve patient health outcomes, particularly in fields where a thorough knowledge of each person's phenotypic and disease profile is crucial.

The demand for personalized medicine is rising globally, notably in the treatment of cancer, as a result of personalized medicine's significant influence on the healthcare sector. The microfluidic systems with integrated stem cells display behaviors that mimic individual organ-level physiology in regulated and dynamic microenvironment circumstances. These unique models aid in the prediction of toxicity and effectiveness for particular patients. Patients will be matched with the most effective medicines in the future by concentrating on early disease identification with the use of personalized medicine.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

• Companies that produce organs on chips are increasingly using big data to manage the data produced by OOCs. The problems that data created from OOCs can overcome include sharing, integrating, and interpreting the data. Implementing big data algorithms on current high-speed computer systems is essential for efficiently using the generated data. In the case of Netri, a France-based company that provides organs-on-chip to the industry, algorithms have been developed to extract the majority of functional network markers OOCs (connectivity map between chambers, the weight of connections, and small worldness of the network) that are compatible with MEA (Micro Electrode Arrays) devices from major suppliers. The industry-standard method for detecting electrophysiological signals is the MEA. Data from ongoing recordings are used to examine how a substance affects functional activity and network dynamics.

Recent Developments

The market for organ on chip is highly competitive. The state of the economy and government assistance have a direct impact on the expansion of businesses. Based on their product's quality and market penetration in both the target and growing markets, these companies distinguish their organ on chip drivers in the industry.

Furthermore, recent important mergers and acquisitions in the sector have had a big impact on the dynamics of competition. For instance:

• In September 2022, Emulate, Inc., a top supplier of next-generation in vitro models, released its new adeno-associated virus (AAV) transduction application for the Liver Chip. This application enables gene therapy researchers to test the effectiveness and safety of AAV vectors for delivery in a validated, human-relevant model of the liver and obtain results in weeks, as opposed to months, as with animal models. With the use of this technique, gene therapy delivery can be optimized while development is sped up.
• In February 2018, to advance their organ-on-chip testing technology, Roche partnered with Emulate, a biotechnology business with headquarters in the USA. Roche intends to make better predictions about the efficacy and safety of its therapeutic prospects using the Emulates Human Emulation system. Through this cooperation, the Swiss pharmaceutical business will have access to Emulates OOC to find and create novel therapeutic antibody classes and medication combinations.
• In April 2017, the US FDA and Emulate Inc. signed an agreement to test the company's human organ-on-chip technology in lab settings. The OOC technology provides a less time-consuming and cost-effective way to test the efficacy and toxicity of medications, foods, cosmetics, and dietary supplements. The first commercial organ-on-chip company is Emulate Inc., which was established by scientists at Harvard University's Wyss Institute for Biologically Inspired Engineering.

Segments Analysis

By Offering Type

The market is segmented into devices and testing services.

By Organ Type

“The lung-on-chip segment is expected to lead the market during the forecast period”.

The market is divided into lung-on-chip, heart-on-chip, liver-on-chip, intestine-on-chip, kidney-on-chip, skin-on-chip, blood-brain-barrier-on-chip, others. Due to fewer lung transplants, which has prompted the development of laboratory-engineered chips to mimic their functions and for drug screening for respiratory disorders, the lung-on-chip segment of the organ-on-chip market has dominated the market since 2021 and is predicted to continue dominating during the forecast period.

By Application Type

The market is further segmented into toxicology research, drug discovery, molecular biology, disease modelling, food safety, and others.

Regional Analysis

“North America held the largest market share and is projected to maintain this position throughout the forecast period”.

The organ on chip market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America held the largest share of the worldwide organ-on-chip market, and it is expected to hold this position throughout the forecast period. 

This is attributable to a growth in the use of technologically advanced models, the presence of important players, and an increase in research and development operations for the development of new drugs.

However, because of an increase in R&D efforts, an increase in healthcare spending, and diverse tactics among key competitors, the Asia-Pacific region is predicted to have a significant organ-on-chip market opportunity. In addition, according to the prediction for the Asia-Pacific organ-on-chip market, India and China would expand at rapid CAGRs.

Key Players

The following are the key players in the Organ on Chip Market (arranged alphabetically)

• AxoSim Inc.
• BEOnChip
• CN Bio Innovations
• Emulate Inc.
• InSphero AG
• Mesobiotech
• Micronit
• Mimetas BV
• Nortis Inc.
• TissUse GmbH

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.